Clinical Trial Update: DALY II USA/ MB-CART2019.1 for DLBCL [Phase 2]

View source ↗

Summary

Miltenyi Biomedicine's MB-CART2019.1 (DALY II) is in Phase 2 for refractory/relapsed B-cell lymphomas, including Diffuse Large B-Cell Lymphoma, and the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Richter Transformation
• Transformed B-cell Lymphoma

Drugs mentioned

• DALY II (MB-CART2019.1) (MB-CART2019.1)

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING